These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25070604)

  • 1. Uremic toxicity and sclerostin in chronic kidney disease patients.
    Desjardins L; Liabeuf S; Oliveira RB; Louvet L; Kamel S; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
    Nephrol Ther; 2014 Nov; 10(6):463-70. PubMed ID: 25070604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study.
    Rossi M; Campbell K; Johnson D; Stanton T; Pascoe E; Hawley C; Dimeski G; McWhinney B; Ungerer J; Isbel N
    Nutr Metab Cardiovasc Dis; 2014 Sep; 24(9):1035-42. PubMed ID: 24880738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between uremic toxins and depression in patients with chronic kidney disease undergoing maintenance hemodialysis.
    Hsu HJ; Yen CH; Chen CK; Wu IW; Lee CC; Sun CY; Chang SJ; Chou CC; Hsieh MF; Chen CY; Hsu CY; Tsai CJ; Wu MS
    Gen Hosp Psychiatry; 2013; 35(1):23-7. PubMed ID: 23044245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.
    Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y
    Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease.
    Rossi M; Campbell KL; Johnson DW; Stanton T; Vesey DA; Coombes JS; Weston KS; Hawley CM; McWhinney BC; Ungerer JP; Isbel N
    Arch Med Res; 2014 May; 45(4):309-17. PubMed ID: 24751327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.
    Lin CJ; Wu V; Wu PC; Wu CJ
    PLoS One; 2015; 10(7):e0132589. PubMed ID: 26173073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease.
    Krishnasamy R; Hawley CM; Stanton T; Pascoe EM; Campbell KL; Rossi M; Petchey W; Tan KS; Beetham KS; Coombes JS; Leano R; Haluska BA; Isbel NM
    BMC Nephrol; 2015 Jul; 16():106. PubMed ID: 26187506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
    Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
    Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Liver in Determining Serum Colon-Derived Uremic Solutes.
    Lin CJ; Liou TC; Pan CF; Wu PC; Sun FJ; Liu HL; Chen HH; Wu CJ
    PLoS One; 2015; 10(8):e0134590. PubMed ID: 26258409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Levels of Total p-Cresylsulfate Are Associated with Pruritus in Patients with Chronic Kidney Disease.
    Wang CP; Lu YC; Tsai IT; Tang WH; Hsu CC; Hung WC; Yu TH; Chen SC; Chung FM; Lee YJ; Houng JY
    Dermatology; 2016; 232(3):363-70. PubMed ID: 27161100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?
    Moysés RM; Jamal SA; Graciolli FG; dos Reis LM; Elias RM
    Int Urol Nephrol; 2015 May; 47(5):847-50. PubMed ID: 25862239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease.
    Claro LM; Moreno-Amaral AN; Gadotti AC; Dolenga CJ; Nakao LS; Azevedo MLV; de Noronha L; Olandoski M; de Moraes TP; Stinghen AEM; Pécoits-Filho R
    Toxins (Basel); 2018 Sep; 10(10):. PubMed ID: 30249039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
    Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM;
    Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between free light chain levels, and disease progression and mortality in chronic kidney disease.
    Desjardins L; Liabeuf S; Lenglet A; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
    Toxins (Basel); 2013 Nov; 5(11):2058-73. PubMed ID: 24217396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of indoxyl sulfate with fibroblast growth factor 23 in patients with advanced chronic kidney disease.
    Lin CJ; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Am J Med Sci; 2014 May; 347(5):370-6. PubMed ID: 24051956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.